Dr. Gregory M. Enns, M.D.
Medical Genetics (Medical Biochemical Genetics)
725 Welch Rd
Palo Alto, CA 94304
Who else practices at this address →
Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 13
Licensed in California since 1993, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Biochemical Genetics primary
CA license A52095 (first issued 1993; current) -
Clinical Biochemical Genetics Physician
CA license A52095 (first issued 1993; current) -
Clinical Genetics (M.D.) Physician
CA license A52095 (first issued 1993; current) · HI license MD-12592
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Lucile Salter PAckard Children's Hsp at Stanford Palo Alto, CA
Medical groups
- Lpch Medical Group Div of Lucile (337 clinicians)
- Kapiolani Medical Specialists (97 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 13
- Services billed
- 13
- Patients’ average age
- 63
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 4 companies reported 5 payments worth $5,275 in total to this clinician.
| Amicus Therapeutics, Inc. | $2,490 |
|---|---|
| UCB SA | $2,288 |
| Tanabe Pharma America, Inc. | $480 |
| Immedica Pharma US, Inc. | $17.77 |
| Consulting Fee | $5,258 |
|---|---|
| Food and Beverage | $17.77 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| UCB SA Jun 20, 2025 | Consulting Fee | $2,288 |
| Amicus Therapeutics, Inc. Feb 5, 2025 | Consulting Fee POMBILITI; OPFOLDA · POMPE DISEASE | $1,575 |
| Amicus Therapeutics, Inc. Aug 6, 2025 | Consulting Fee POMBILITI; OPFOLDA · POMPE DISEASE | $915 |
| Tanabe Pharma America, Inc. Jan 16, 2025 | Consulting Fee | $480 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 5 companies. The companies reported $391,478 in research payments for these studies, mostly to the institutions running them.
- An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705
ModernaTX, Inc. · Recruiting · NCT05295433 - A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
Ptc Therapeutics, Inc. · Completed · NCT05218655 - A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia
ModernaTX, Inc. · Terminated · NCT04899310 - US-Based Retrospective Medical Record Review of Patients with Methylmalonic Acidemia (MMA) Undergoing Liver or Combined Liver-Kidney Transplants (LT/LKT)
ModernaTX, Inc. - Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
ModernaTX, Inc. · Recruiting · NCT04159103 - Gaucher disease outcome survey (gos) an observational, international, multicenter, long-term registry of patients with gaucher disease
Takeda Pharmaceuticals U.S.A., Inc. - EPI-743 for Mitochondrial Respiratory Chain Diseases
Ptc Therapeutics, Inc. · No longer available · NCT01370447 - A Randomized, Double blind, Placebo controlled Adaptive Phase 2/3 Study With Open label Extension to Assess the Efficacy, Safety and Tolerability of ASP0367 in Participants With Primary Mitochondrial Myopathy
Astellas Pharma Inc - A Prospective, Observational, Non-Interventional, Post-Marketing, Patient Registry to Collect Data on Routine Clinical Care in Patients Treated With Cholbam (Cholic Acid) (REPLACE)
Mirum Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.